Baidu
map

Stroke:高密度脂蛋白胆固醇与总的、缺血性和出血性卒中发生率的U型关系

2022-01-30 MedSci原创 MedSci原创

较低和较高的平均累积HDL-C均与缺血性卒中和出血性卒中风险增加相关。

大多数的研究提示甘油三脂水平升高与缺血性卒中发生风险增加密切相关,但是,高密度脂蛋白胆固醇(HDL-C)水平与卒中之间的关系存在相互矛盾的地方。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,在这一项前瞻性队列研究中,研究人员旨在调查连续测量的HDL-C水平与卒中风险之间的关联。

研究人员纳入了96258名个体(79.6%为男性,平均年龄为51.5岁),在开滦研究中,受试者基线时没有卒中、心肌梗死或癌症病史,并在2006年、2008年、2010年、2012年、2014年和2016年重复测量了HDL-C水平。

研究人员使用所有可用的HDL-C测量值在卒中发生或随访(2017年12月31日)结束之前计算了平均HDL-C浓度。研究人员通过查阅病历确认了卒中病例,并进一步细分为缺血性或出血性卒中。研究人员采用Cox比例风险回归和限制三次样条评估了这些关联。

在10.7年的中位随访期间,该研究共发生了5012例卒中事件。受限三次样条分析表明,累积平均HDL-C浓度与卒中风险之间存在U型关联(非线性P<0.001),风险最低值为1.29mmol/L。在调整心血管危险因素后,累积平均HDL-C≤1.06mmol/L或≥2.05mmol/L个体的总卒中风险比为1.31(95%CI为1.15-1.49)和1.85(1.63-2.09),相比于HDL-C为1.26至1.39mmol/L的个体。缺血性卒中的相应风险比分别为1.29(1.11-1.48)和1.84(1.60-2.11),出血性卒中的相应风险比分别为1.54(1.12-2.12)和2.29(1.73-3.04)。

由此可见,较低和较高的平均累积HDL-C均与缺血性卒中和出血性卒中风险增加相关。

原始出处:

Haibin Li.et al.U-Shaped Relationship of High-Density Lipoprotein Cholesterol and Incidence of Total, Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study.stroke.2022.https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.034393

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
    2022-03-23 ms6000000123128583

    牛的

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
    2022-01-30 查查佳佳

    杂志Stroke上发表了一篇研究文章,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
    2022-01-29 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
    2022-01-29 1581f400dfm

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1826769, encodeId=3b7d1826e692c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 27 13:26:59 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205267, encodeId=cd98120526e65, content=牛的 , beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ba26557613, createdName=ms6000000123128583, createdTime=Wed Mar 23 16:50:54 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893472, encodeId=9b5b18934e2fd, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Aug 10 05:26:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319573, encodeId=2abc13195e3bc, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424823, encodeId=6507142482308, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462991, encodeId=cf2e1462991d8, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Mon Jan 31 07:26:59 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189279, encodeId=6c9511892e96d, content=杂志Stroke上发表了一篇研究文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Jan 30 12:12:09 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189208, encodeId=f51f118920819, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 29 23:16:10 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189139, encodeId=b9011189139c0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35842089681, createdName=1581f400dfm, createdTime=Sat Jan 29 19:33:14 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189138, encodeId=ad30118913828, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Jan 29 19:25:37 CST 2022, time=2022-01-29, status=1, ipAttribution=)]
    2022-01-29 robbert123

    学习

    0

相关资讯

Stroke:这7种药物可能诱发缺血性卒中,谨慎使用!

药物相关性缺血性脑卒中,是指因药物使用导致血管内皮功能障碍、凝血改变或纤维蛋白溶解等异常,进而导致缺血性脑卒中的发生。

Neurology:独立于传统血管危险因素,循环白细胞介素-6(IL-6)水平与发生缺血性卒中长期风险呈正线性相关!

近日,研究人员利用已发表/未发表研究进行系统回顾和荟萃分析,探索基于人群的前瞻性队列研究中循环IL-6水平与缺血性卒中发病风险的关系,证实了较高的IL-6水平与较高的发生缺血性卒中长期风险呈线性关系。

JAMA:两个简单量表指导PFO闭合术的决策

在18-60岁青壮年和中年人缺血性卒中中,卵圆孔未闭(PFO)相关性卒中占10%。预防PFO相关缺血性卒中患者复发性卒中的治疗策略包括抗血栓治疗或经皮PFO封堵,每种治疗策略都在实践指南中得到认可。

Stroke:缺血性卒中后,血脑屏障破坏和低灌注,和脑水肿相关

再灌注治疗后梗死区的BBB破坏和持续的低灌注与占位性脑水肿有关

Stroke:缺血性卒中,有哪些心源性的风险因素

现有的遗传数据并不支持心脏特征对已知临床危险因素以外的卒中风险的实质性影响

Neurology:1990-2019年全球缺血性卒中疾病负担:中国年龄标准化发病率(ASIR)增长最为显著,全球范围内女性缺血性卒中负担较大,老龄尤甚

近日,有研究人员对GBD 2019年的数据进行了缺血性卒中的分析, 在中等、中-高等SDI地区,ASIR、ASDR和年龄标化DALY率仍然较高。全球范围内,女性缺血性卒中负担大于男性,50岁以上尤甚。

Baidu
map
Baidu
map
Baidu
map